All In Biotech

Drug Trial Radar · NCT06478706

A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis

A Randomised, Double-Blind, Placebo Controlled, Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Repeat Dose of Inhaled ETD001 in People With Cystic Fibrosis

Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

57

Actual

Start

Jun 26, 2024

Primary completion

Nov 14, 2025

Study completion Nov 14, 2025

Sponsor

Lead sponsor
Enterprise Therapeutics LtdIndustry
Sponsor type
Industry
First posted
Jun 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is the first to give ETD001 to people with CF. The study will be run in two parts. Part A will assess if ETD001 is safe to give to people with CF, and Part B will assess if ETD001 improves lung function. The study drug is taken twice a day, in Part A it is taken for 7 days and in Part B for 28 days. In Part B there will be a separate period where dummy medicine is given for 28 days so the treatments can be compared. In Part A participants will receive 13 doses of either ETD001 or placebo, 8 people will take part. Participants will take up to 56 days to finish the study and make 5 outpatient visits. In Part B participants will receive 55 doses of ETD001 and 55 doses of placebo, 32 people will take part. Participants will take up to 140 days to finish the study and will make 8 outpatient visits. Study assessments include physical examinations, vital signs, heart traces, blood/urine samples, breathing tests and health questionnaires.

Conditions

  • Cystic Fibrosis

Interventions

  • ETD001Drug

    Twice daily doses

  • PlaceboDrug

    Twice daily doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and tolerability of repeat inhaled doses of ETD001 monitored by assessment of adverse eventsTime frame: 28 days
  2. Part B: Effect of repeat inhaled doses of ETD001 on percent predicted forced expiratory volume in 1 second (ppFEV1)Time frame: Treatment Period 1 & 2 - Day 1 (pre-dose, 1, 2 & 4 hours post dose), Day 14 (pre-dose, 1 & 2 hours post), Day 28 (at 0, 1, 2 & 4 hours post dose)

Locations

21 sites in 4 countries. Site status is shown where the registry gives one.

  • Hospices Civils de Lyon

    Lyon, France

  • CHU de Montpellier

    Montpellier, France

  • Hôpital Cochin

    Paris, France

  • Hôpitaux de Toulouse

    Toulouse, France

  • Charité Universtaetsmedizin

    Berlin, Germany

  • CF-Studienzentrum Universitätsklinikum Köln

    Cologne, Germany

  • Westdeutsches Lungenzentrum am Universitätsklinikum

    Essen, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

  • IKF Pneumologie

    Frankfurt, Germany

  • LMU Kinikum

    Munich, Germany

  • Azienda Ospedaliera Universitaria Meyer

    Florence, Italy

  • IRCCS Istituto Giannina Gaslini

    Genova, Italy

  • Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

    Milan, Italy

  • Ospedale Pediatrico Bambino Gesù

    Roma, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, Italy

  • Belfast Health and Social Care Trust

    Belfast, United Kingdom

  • Royal Papworth Hospital

    Cambridge, United Kingdom

  • All Wales Adult CF Centre

    Cardiff, United Kingdom

  • Queen Elizabeth University Hospital West of Scotland CF Service

    Glasgow, United Kingdom

  • Royal Brompton Hospital

    London, United Kingdom

  • Southampton General Hospital

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.